Unveiling 'Hexa' HIFU Technology with Dynamic Zoom Laser and Advanced Drug Delivery CapabilitiesBTB Korea has launched a global market offensive by unveiling three new proprietary medical devices. The new lineup includes the world's first 1726nm fractional laser, a HIFU-based drug delivery platform, and a homecare device, signaling a major move to demonstrate its technological competitiveness in the dermatology and medical device markets.BTB Korea announced on the 13th that it first showcased the three new products at 'KIMES 2026', Korea's largest medical device exhibition, held from March 19 to 22. The company is simultaneously pursuing domestic and international regulatory approvals, targeting sequential launches between the end of the second quarter and the third quarter of this year.The flagship product unveiled is the 1726nm fractional laser. Equipped with a proprietary 'Dynamic Zoom' feature, it allows real-time adjustment of the spot size, enabling precise control of lesions based on treatment area and depth. Furthermore, it incorporates an artificial intelligence (AI)-based mechanism that automatically optimizes laser pulse shapes and widths, expanding precision and applicability compared to conventional fractional lasers.The second product is a platform utilizing 'Hexa' spatio-temporally dispersed HIFU technology. By rapidly dispersing focal points in space and time, it precisely treats broad three-dimensional areas, offering not only non-invasive lifting but also drug delivery capabilities. Notably, it presents the potential to deliver therapeutic agents, such as anti-cancer drugs, to deep tissues including the blood-brain barrier (BBB), raising expectations for its expansion into various medical fields such as inflammation, pain, and cancer treatment support.The third product is a homecare device that scales down clinical-grade technology for home use. This is part of a two-track strategy combining B2C with the existing B2B-focused business structure, aimed at driving top-line growth by broadening touchpoints in the consumer market.Alongside the new product launches, BTB Korea is expanding its recruitment of core talent to strengthen its R&D, sales, and marketing organizations. Additionally, the company plans to pursue a stock reverse split (stock consolidation) to enhance stock price stability and corporate value.

Global Bio Company BNC Korea Launches Premium Home Beauty Brand ‘I.st LUCENIA’Global bio-company BNC Korea announced on the 10th the launch of its premium home beauty brand, 'I.st LUCENIA.' LUCENIA is a next-generation home beauty device brand that combines hospital-grade dermatological medical device technology with a sensory cosmetic user experience.LUCENIA is the first B2C brand introduced since BNC Korea acquired BTB Korea, a company specializing in aesthetic medical devices. Designed based on BTB Korea's medical device technology for clinics, the brand is evaluated to have effectively achieved a "balance between technology and aesthetics," grounded in a precise understanding of skin structure and an analysis of actual users' daily routines.Coinciding with the brand launch, two models are being introduced: 'Dual Shine' and 'Hi-Fit.'The 'LUCENIA Dual Shine' integrates five core technologies—RF (Radio Frequency), Laser, Microcurrent, Electroporation, and LED—enabling simultaneous care for both the skin and the scalp.The 'LUCENIA Hi-Fit' centers on unlimited-use HIFU (High-Intensity Focused Ultrasound) and integrates premium, clinic-level technologies such as dual-cross ultrasound, RF, and Electroporation. By applying patented technology, it allows for easy adjustment of the penetration depth for specific areas—such as around the eyes, cheeks, and jawline—delivering a highly precise lifting effect tailored to the user's skin condition. Additionally, it offers three intensive care modes ('Beauty', 'Exercise', and 'Pro') to effectively manage various skin concerns in daily life, including elasticity, contouring, radiance, soothing, and pores.Vice President Ryu Nam-joo, head of BNC Korea’s cosmetic brand I.st, stated, “LUCENIA is a home beauty device that provides solutions tailored to skin concerns through the synergy of biotechnology, derma-cosmetics, and beauty devices. Differentiating itself from devices that merely compile functions, it will act as a game changer in the market.” He further added, “Following our domestic launch, we plan to enter the U.S. and Chinese markets—which are currently under negotiation—within the third quarter, expanding the global presence of 'K-Beauty' and 'K-Device'.”BNC Korea is a bio-group dedicated to the research of skin elasticity. The company is generating strong expectations for its global market expansion, having completed an integrated healthcare platform that encompasses global medical devices such as botulinum toxin and dermal fillers, alongside cosmetics, medical equipment, and home care beauty devices.

Anticipating Synergy in K-Beauty and Aesthetic Medical Devices: "Confident to Lead the Global K-Beauty Trend"On the 19th, marking the resumption of BTB Korea’s stock trading on the KOSDAQ, CEO Choi Wan-kyu of BNC Korea stated, "The resumption of BTB Korea’s trading goes beyond the successful completion of the corporate rehabilitation process. It serves as a catalyst for a new leap forward in the global medical and bio market through strengthened strategic synergy with BNC Korea."He further added, "By integrating BNC Korea's core K-Beauty portfolio—including botulinum toxin, dermal fillers, and cosmetics—with BTB Korea’s aesthetic medical device lineup, we aim to provide comprehensive total aesthetic solutions, thereby maximizing profitability and growth potential."After initiating the rehabilitation process in April 2023, BTB Korea secured a crucial turning point by signing an investment agreement with BNC Korea, a KOSDAQ-listed company, in November 2023. Following the approval of the rehabilitation plan in December 2023, BTB Korea successfully merged with Dongin Biotech, a subsidiary of BNC Korea, in March 2024. This strategic move established a stable revenue structure and a solid foundation for bio-distribution.The global aesthetic medical device market is projected to reach approximately 623 trillion KRW by 2031, growing at a compound annual growth rate (CAGR) of 11.1%. Notably, the home beauty device sector is expanding rapidly with a 36% growth rate, expected to reach about 45 trillion KRW by 2030. Driven by sustainable consumption trends in an era of high inflation, these devices are gaining traction as cost-effective alternatives. Demand is also surging in regions with limited medical infrastructure.The outstanding IT and precision manufacturing technologies of Korean enterprises are the backbone of the global competitiveness of the K-Beauty device industry. Leveraging this industrial foundation and strategic partnerships, BTB Korea is actively expanding its global footprint.Dongin Biotech is a highly profitable entity specialized in the distribution of diagnostic kits and bio-materials, generating consistent revenue in the life sciences and research reagents sector. Through this merger, BTB Korea recorded a revenue of 30.1 billion KRW and an operating profit of 900 million KRW last year.Furthermore, drawing upon over 20 years of research support expertise, BTB Korea has completed the development of 'BTBMarket.kr'. This AI solution platform is designed to enhance research efficiency by providing researchers with empirically based experimental materials and methodologies. Scheduled for a beta launch in March 2025 and a grand opening with advanced features in July 2025, BTBMarket.kr is anticipated to introduce a new paradigm in the domestic and global life sciences sectors.Industry assessments indicate that BTB Korea’s trading resumption signifies more than just recovery. The integration of BNC Korea’s aesthetic product line (toxins and fillers), BTB Korea’s medical device lineup, and Dongin Biotech’s bio-distribution network has completed a vertically integrated business structure encompassing R&D, manufacturing, and distribution.CEO Choi Wan-kyu remarked, "This trading resumption signals the realization of powerful synergy between the two companies. We are confident that our organization will become a primary driver of the K-Beauty trend in the global market."[About BTB Korea]BTB Korea is a KOSDAQ-listed company specializing in the manufacturing and distribution of aesthetic medical devices. The company is advancing into the global aesthetic and medical markets with a primary focus on RF and HIFU-based solutions. Following its merger and acquisition by BNC Korea, the company has successfully expanded its business portfolio by incorporating bio-distribution operations.